ClinicalTrials.gg
Not yet recruitingNCT06559722Updated Aug 19, 2024

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes

A Phase 3 interventional study of Insulin Degludec/liraglutide Injection and XULTOPHY® in Type 2 Diabetes, sponsored by Tonghua Dongbao Pharmaceutical Co.,Ltd. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-19.

Sponsored by Tonghua Dongbao Pharmaceutical Co.,Ltd · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
510
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Planned enrollment
16th of 70
510 · median 384
Started
2024
the only one that year
Phase 3
49 of 70
2 open now
Registered
68th of 70
by date
Lead sponsor
1 of 70
Tonghua Dongbao Pharmaceutical Co.,Ltd

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 16th largest by planned enrollment, is the only one that started in 2024, is one of 49 in phase 3, and was the 68th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a randomised, open-label, multicenter, active-controlled, parallel-design, phase III clinical trial. The purpose of this study to compare the efficacy and safety of Insulin Degludec/Liraglutide Injection with XULTOPHY® once daily via subcutaneous injection in Chinese Subjects with Type 2 Diabetes.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who voluntarily participate in this clinical trial and signed the form (ICF);
  • Chinese subjects aged 18-75 years (both inclusive) at the time of consent, male or female;
  • Type 2 diabetes mellitus (clinically diagnosed for more than 6 months);
  • HbA1c7.0-10.0 % (both inclusive) by central laboratory analysis at the time of screening;
  • Current treatment for at least 90 calendar days prior to screening with metformin monotherapy or metformin in any combination with 1 additional OADs (including fixed combination): SU, glinides, AGI, SGLT2i or TZD. For ≥ 60 calendar days prior to screening subjects should be on a stable dose of:

    1. Metformin (≥ 1500 mg or at maximum tolerated dose) or
    2. Metformin (≥1500 mg or max tolerated dose) and SU (≥half of the max approved dose according to local label) or
    3. Metformin (≥1500 mg or max tolerated dose) and glinides (≥half of the max approved dose according to local label) or
    4. Metformin (≥1500 mg or max tolerated dose) and AGI (≥half of the max approved dose according to local label) or
    5. Metformin (≥1500 mg or max tolerated dose) and SGLT2i (≥half of the max approved dose or minimum maintenance dose such as empagliflozin 10 mg and canagliflozin 100 mg according to local label) or
    6. Metformin (≥1500 mg or max tolerated dose) and TZD (≥half of the max approved dose according to local label);
  • (BMI) ≥ 19.0 kg/m2 and ≤ 40 kg/m2;
  • Able and willing to adhere to the protocol including performing self-monitoring of plasma glucose profiles, keeping a trial diary and using a pre-filled pen device.

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from the study:

  • Subjects with diabetes of other types than T2DM;
  • Known or suspected to trial product(s) or related components;
  • Participated in any clinical trial and Receipt of any treatment of medicinal product (IMP) or medical device within 90 days prior screening;
  • Treatment with glucose lowering agent(s) other than stated in the inclusion criteria 5 for cumulatively more than 14 days in a period of 90 days before screening; or treatment with these agent(s) in a period of 30 days before screening and might influence the assessment of efficacy of glycemic control (Judged by the investigator);
  • Treatment with systemic for cumulatively more than 14 days in a period of 90 days before screening (including intravenous, muscle and subcutaneous injections, and oral administration, except for local, intraocular, nasal, intraarticular, and inhalation medications); or treatment with these agent(s) in a period of 30 days before screening and might influence the assessment of efficacy (Judged by the investigator);
  • Treatment with glucose lowering agent(s) of herbal traditional Chinese medicine or other local herbal medicines for cumulatively more than 14 days in a period of 90 days before screening; or treatment with these agent(s) in a period of 30 days before screening and might influence the assessment of efficacy (Judged by the investigator);
  • Treated with stable insulin regimen (except for short-term treatment (e.g., no more than 14 days of continuous treatment)), or treatment with insulin in a period of 30 days before screening and might influence the assessment of efficacy (Judged by the investigator);
  • Treatment with GLP-1 receptor agonists or DPP-4 inhibitors within 90 calendar days prior to screening;
  • Impaired liver function, defined as aspart aminotransferase () or alanine aminotransferase (ALT) ≥ 2.5 times or a total level (TBIL) ≥ 1.5 times upper limit of the normal;
  • Triglycerides >5.6 mmol/L at screening;
  • Impaired renal function, defined as (Ccr) of less than 60 mL/min (calculated from the Cockcroft-Gault formula);
  • Have had 1 or more episodes of severe hypoglycemia within the 6 months prior to screening.
  • Have had 1 or more episodes of acute diabetic complications (diabetic ketoacidosis, hyperglycemic hyperosmolar state, diabetic lactic acidosis, etc.) within the 6 months prior to screening.
  • With concomitant conditions at screening that may affect the evaluation of the study, including cardiovascular and cerebrovascular diseases, respiratory diseases, gastrointestinal diseases, liver diseases, kidney diseases, nervous system diseases, psychiatric diseases, hematological diseases, immune system diseases, endocrine system diseases, pancreatic diseases, and/or malignant tumors.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
510 participants (estimated)

Study arms

  • Experimental
    Insulin Degludec/liraglutide injection

    Subcutaneously (s.c., under the skin) administration once daily in combination with metformin. Dose was individually adjusted.

    Drug: Insulin Degludec/liraglutide Injection

  • Active comparator
    XULTOPHY®

    Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. Dose was individually adjusted.

    Drug: XULTOPHY®

Interventions

  • DrugInsulin Degludec/liraglutide Injection

    Drug pages: Insulin degludec · Liraglutide

    Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. Dose was individually adjusted.

  • DrugXULTOPHY®

    Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. Dose was individually adjusted.

06

What researchers measure

Primary outcomes

  1. Change from baseline in HbA1c after 26 weeks of treatment

    Calculated based on HbA1c level measured in plasma

    Time frame: Baseline, Week 26

Secondary outcomes

  1. Proportion of subjects that achieved HbA1c<7% after 12, 26 weeks of treatment

    Calculated based on HbA1c level measured in plasma

    Time frame: Week 12, Week 26

  2. Proportion of subjects that achieved HbA 1c ≤ 6.5% after 12, 26 weeks of treatment

    Calculated based on HbA1c level measured in plasma

    Time frame: Week 12, Week 26

  3. Changes from baseline in fasting plasma glucose (FPG) after 12, 26 weeks of treatment

    Calculated based on FPG level measured in plasma

    Time frame: Baseline, Week 12, Week 26

  4. Change from baseline in 7-point SMBG values after 12, 26 weeks of treatment

    Calculated based on 7-point SMBG values

    Time frame: Baseline, Week 12, Week 26

  5. Change from baseline in body weight after 12, 26 weeks of treatment

    Calculated based on body weight measurement

    Time frame: Baseline, Week 12, Week 26

  6. Number of treatment emergent adverse events

    Count

    Time frame: From Baseline to Week 27

  7. Number of treatment emergent hypoglycaemic episodes

    Count

    Time frame: From Baseline to Week 27

  8. Number of participants with injection site reactions

    Count (spontaneous pain, tenderness, itching, redness, edema, induration/infiltration)

    Time frame: From Baseline to Week 27

  9. Incidence of anti-drug antibodies (ADA), and neutralising antibodies (if applicable)

    Calculated based on the values of anti-drug antibodies (ADA), and neutralising antibodies (if applicable)

    Time frame: Baseline, Week 12, 26, and 27 (if applicable)

  10. Plasma concentrations of degludec, liraglutide

    Calculated based on plasma concentrations of degludec, liraglutide

    Time frame: Baseline, Week 2, 6, 12, 20, 26

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2024; primary completion for Oct 2025, 14 months later.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 14 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2024
First posted
Aug 19, 2024
StartEst.
Aug 2024
Primary completionEst.
Oct 2025
CompletionEst.
Feb 2026
Last update
Aug 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06559722
Lead sponsor
Tonghua Dongbao Pharmaceutical Co.,Ltd
Responsible party
Sponsor
First posted
Aug 19, 2024
Start date
Aug 2024 (estimated)
Primary completion
Oct 2025 (estimated)
Completion
Feb 2026 (estimated)
Last update
Aug 19, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Liraglutide

Start the discussion